Skip to main content

Advertisement

Log in

Association Between Adipokines Levels with Inflammatory Bowel Disease (IBD): Systematic Reviews

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

A combination of genetic and environmental factors is involved in the etiology of inflammatory bowel disease (IBD). Recent studies have shown that adipocytes play a crucial role, by actively participating in systemic immune responses in IBD patients. But findings remain controversial. To the best of our knowledge, no systematic review has evaluated the roles of adipokines in IBD, considering which this systematic review was undertaken to summarize the effects of these adipokines in IBD pathogenesis.

Methods

For this review, articles published between 1980 and 2016 were identified from the PubMed, EMBASE, Scopus, and Cochrane and Google scholar databases. Thirteen articles were ultimately selected for inclusion in this systematic review.

Results

Findings of the present study indicate that some of the adipokines such as leptin, adiponectin and resistin are associated with disease severity, body composition and glucose hemostasis in IBD patients, although some of these associations are stronger than others.

Conclusions

Overall findings indicate that some adipokines may play a crucial role in IBD severity or other IBD related outcomes. Further studies are recommended to confirm the results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182–205.

    Article  CAS  PubMed  Google Scholar 

  2. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12:205–217.

    Article  PubMed  Google Scholar 

  3. Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg. 1998;22:382–389.

    Article  CAS  PubMed  Google Scholar 

  4. Ghigliotti G, Barisione C, Garibaldi S, et al. Adipose tissue immune response: novel triggers and consequences for chronic inflammatory conditions. Inflammation. 2014;37:1337–1353.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Paz-Filho G, Mastronardi C, Franco CB, Wang KB, Wong M-L, Licinio J. Leptin: molecular mechanisms, systemic pro-inflammatory effects, and clinical implications. Arq Bras Endocrinol Metabol. 2012;56:597–607.

    Article  PubMed  Google Scholar 

  7. Barbier M, Vidal H, Desreumaux P, et al. Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol Clin Biol. 2003;27:987–991.

    CAS  PubMed  Google Scholar 

  8. Singh UP, Singh NP, Guan H, et al. The emerging role of leptin antagonist as potential therapeutic option for inflammatory bowel disease. Int Rev Immunol. 2014;33:23–33.

    Article  CAS  PubMed  Google Scholar 

  9. Ruan H, Dong LQ. Adiponectin signaling and function in insulin target tissues. J Mol Cell Biol.. 2016;8:101–109.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007;380:24–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Ghomraoui FA, Alotaibi ST, Alharthi MA, et al. Plasma ghrelin and leptin in patients with inflammatory bowel disease and its association with nutritional status. Saudi J Gastroenterol. 2017;23:199–205. PubMed PMID: 28611344. Pubmed Central PMCID: PMC5470380. Epub 06/15/2017. eng.

  12. Al-Suhaimi EA, Shehzad A. Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur J Med Res. 2013;18:12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007;178:1748–1758.

    Article  CAS  PubMed  Google Scholar 

  14. Terzoudis S, Malliaraki N, Damilakis J, Dimitriadou DA, Zavos C, Koutroubakis IE. Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2016;28:814–819.

    Article  CAS  PubMed  Google Scholar 

  15. Laiguillon M-C, Houard X, Bougault C, et al. Expression and function of visfatin (Nampt), an adipokine-enzyme involved in inflammatory pathways of osteoarthritis. Arthritis Res Ther. 2014;16:R38.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8:2–10. PubMed PMID: 25594108. Epub 01/17/2015. eng.

  17. Aurangzeb B, Leach ST, Lemberg DA, Day AS. Assessment of nutritional status and serum leptin in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;52:536–541.

    Article  CAS  PubMed  Google Scholar 

  18. Bannerman E, Davidson I, Conway C, Culley D, Aldhous M, Ghosh S. Altered subjective appetite parameters in Crohn’s disease patients. Clin Nutr. 2001;20:399–405.

    Article  CAS  PubMed  Google Scholar 

  19. Tuzun A, Uygun A, Yesilova Z, et al. Leptin levels in the acute stage of ulcerative colitis. J Gastroenterol Hepatol. 2004;19:429–432.

    Article  CAS  PubMed  Google Scholar 

  20. Rodrigues V, Milanski M, Fagundes J, et al. Serum levels and mesenteric fat tissue expression of adiponectin and leptin in patients with Crohn’s disease. Clin Exp Immunol. 2012;170:358–364.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Valentini L, Wirth EK, Schweizer U, et al. Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease. Nutrition. 2009;25:172–181.

    Article  CAS  PubMed  Google Scholar 

  22. Dogan S, Guven K, Celikbilek M, Deniz K, Saraymen B, Gursoy S. Serum visfatin levels in ulcerative colitis. J Clin Lab Anal. 2015;30:552–556.

    Article  PubMed  Google Scholar 

  23. Konrad A, Lehrke M, Schachinger V, et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol. 2007;19:1070–1074.

    Article  CAS  PubMed  Google Scholar 

  24. Weigert J, Obermeier F, Neumeier M, et al. Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn’s disease. Inflamm Bowel Dis. 2010;16:630–637.

    Article  PubMed  Google Scholar 

  25. Chouliaras G, Panayotou I, Margoni D, et al. Circulating leptin and adiponectin and their relation to glucose metabolism in children with Crohn’s disease and ulcerative colitis. Pediatr Res. 2013;74:420–426.

    Article  CAS  PubMed  Google Scholar 

  26. Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:100–105.

    Article  PubMed  Google Scholar 

  27. Abdel Kader N, Ali El-Din F, Khatab EA, ELAbd N. Does plasma resistin level have a role in predicting inflammatory bowel disease activity? Indian J Gastroenterol. 2010;29:126–127.

    Article  Google Scholar 

  28. Ahishali E, Ercan S, Dolapcioglu C, Dabak R, Kaptanagasi A, Bayramicli O. P140 The relation between resistin and insulin resistance in inflammatory bowel disease patients. J Crohn’s Colitis. 2012;6:S65–S66.

    Article  Google Scholar 

  29. Bruun JM, Pedersen SB, Kristensen K, Richelsen B. Effects of pro-inflammatory cytokines and chemokines on leptin production in human adipose tissue in vitro. Mol Cell Endocrinol. 2002;190:91–99.

    Article  CAS  PubMed  Google Scholar 

  30. Franchimont D, Roland S, Gustot T, et al. Impact of infliximab on serum leptin levels in patients with Crohn’s disease. J Clin Endocrinol Metab. 2005;90:3510–3516.

    Article  CAS  PubMed  Google Scholar 

  31. Tiaka EK, Manolakis AC, Kapsoritakis AN, Potamianos SP. Unraveling the link between leptin, ghrelin and different types of colitis. Ann Gastroenterol. 2011;24:20–28. PubMed PMID: 24714276. Pubmed Central PMCID: PMC3959465. Epub 01/01/2011. eng.

  32. Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch. 2007;455:479–492. PubMed PMID: 17609976. Pubmed Central PMCID: PMC2040175. Epub 07/05/2007. eng.

  33. Neumeier M, Weigert J, Schäffler A, et al. Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol. 2006;79:803–808.

    Article  CAS  PubMed  Google Scholar 

  34. Yamaguchi N, Argueta JGM, Masuhiro Y, et al. Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett. 2005;579:6821–6826.

    Article  CAS  PubMed  Google Scholar 

  35. Kaser A, Tilg H. “Metabolic aspects” in inflammatory bowel diseases. Curr Drug Deliv. 2012;9:326–332.

    Article  CAS  PubMed  Google Scholar 

  36. Paul G, Schäffler A, Neumeier M, et al. Profiling adipocytokine secretion from creeping fat in Crohn’s disease. Inflamm Bowel Dis. 2006;12:471–477.

    Article  PubMed  Google Scholar 

  37. Kaser S, Kaser A, Sandhofer A, Ebenbichler C, Tilg H, Patsch J. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun. 2003;309:286–290.

    Article  CAS  PubMed  Google Scholar 

  38. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-α and IL-12 in macrophages by NF-κB-dependent pathway. Biochem Biophys Res Commun. 2005;334:1092–1101.

    Article  CAS  PubMed  Google Scholar 

  39. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 2006;580:2917–2921.

    Article  CAS  PubMed  Google Scholar 

  40. Koutroubakis IE, Oustamanolakis P, Malliaraki N, et al. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2009;21:283–288.

    Article  CAS  PubMed  Google Scholar 

  41. Scoville AE, Brown C, Allaman M, et al. Differences in serum adipokines between Crohn’s disease and ulcerative colitis patients indicate that they may represent non-invasive biomarker. Gastroenterology. 2016;150:380–389.

    Article  Google Scholar 

Download references

Acknowledgment

The authors wish to acknowledge Ms. Niloofar Shiva for critical editing of English grammar and syntax of the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Parvin Mirmiran.

Ethics declarations

Conflict of Interest

The authors declare no competing financial interests relevant to the present work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morshedzadeh, N., Rahimlou, M., Asadzadeh Aghdaei, H. et al. Association Between Adipokines Levels with Inflammatory Bowel Disease (IBD): Systematic Reviews. Dig Dis Sci 62, 3280–3286 (2017). https://doi.org/10.1007/s10620-017-4806-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-017-4806-5

Keywords

Navigation